1h Free Analyst Time
The bispecific antibodies for cancer market is forecasted to grow by USD 338 million during 2024-2029, accelerating at a CAGR of 6.9% during the forecast period. The report on the bispecific antibodies for cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cancer, advantages of bispecific antibodies over monoclonal antibodies, and strong pipeline of bispecific antibodies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The bispecific antibodies for cancer market is segmented as below:
By Type
- CD19 or CD3
- CD30 or CD16A
By Distribution Channel
- Hospitals
- Retail pharmacies
- Online
By Action Mechanism
- Dual antigen targeting
- Dual-blocking antibodies
- T-cell engagers
By Therapeutic Area
- Oncology
- Autoimmune diseases
- Infectious diseases
- Neurological disorders
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the bispecific antibodies for cancer market covers the following areas:
- Bispecific Antibodies For Cancer Market sizing
- Bispecific Antibodies For Cancer Market forecast
- Bispecific Antibodies For Cancer Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Distribution Channel
10 Market Segmentation by Action Mechanism
11 Market Segmentation by Therapeutic Area
12 Customer Landscape
13 Geographic Landscape
14 Drivers, Challenges, and Opportunity/Restraints
15 Competitive Landscape
16 Competitive Analysis
17 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global bispecific antibodies for cancer market: ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Xencor Inc., and Y mAbs Therapeutics Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emerging bispecific antibody generation platforms."
According to the report, one of the major drivers for this market is the increasing prevalence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABL Bio Inc.
- AFFIMED N.V.
- Akeso Inc.
- Amgen Inc.
- Aptevo Therapeutics Inc.
- Astellas Pharma Inc.
- Chugai Pharmaceutical Co. Ltd.
- Eli Lilly and Co.
- EPIMAB BIOTHERAPEUTICS INC.
- F STAR THERAPEUTICS INC.
- F. Hoffmann La Roche Ltd.
- Glenmark Pharmaceuticals Ltd.
- Johnson and Johnson Services Inc.
- Mereo BioPharma Group Plc
- Merus N.V.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- TG Therapeutics Inc.
- Xencor Inc.
- Y mAbs Therapeutics Inc.
